Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives

Background

Learn About Us

Latest news

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

29th April 2025

BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar

26th March 2025

BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients

17th March 2025

BerGenBio announces advancement of its strategic review

26th February 2025

BerGenBio Fourth Quarter Results 2024

25th February 2025

BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives

18th February 2025

BerGenBio ASA: Invitation to fourth quarter 2024 results webcast

7th January 2025

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

26th November 2024

BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

20th November 2024

BerGenBio Appoints Olav Hellebø as CEO